3-ethyl-9,10-dimethoxy-2-((1,2,3,4-tetrahydroisoquinolin-1-yl)methyl)-4,6,7,11b-tetrahydro-1H-pyrido[2,1-a]isoquinoline | 913523-64-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 3-ethyl-9,10-dimethoxy-2-((1,2,3,4-tetrahydroisoquinolin-1-yl)methyl)-4,6,7,11b-tetrahydro-1H-pyrido[2,1-a]isoquinoline
• 英文别名: NSC 134753；NZ28；3-ethyl-9,10-dimethoxy-2-(1,2,3,4-tetrahydroisoquinolin-1-ylmethyl)-4,6,7,11b-tetrahydro-1H-benzo[a]quinolizine
• CAS: 913523-64-5
• 化学式: C₂₇H₃₄N₂O₂
• 分子量: 418.579
• InChiKey: HDIJLRXRAJUXQB-UHFFFAOYSA-N

物化性质

• 沸点：
  558.8±50.0 °C(Predicted)
• 密度：
  1.17±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  33.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-乙基丙烯酸 在 C₂₇H₃₀Cl₂N₂O₃Ru 、 四丁基氟化铵 、 二异丁基氢化铝 、 叔丁基二甲基氯硅烷 、 三乙胺 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 甲苯 、 乙腈 为溶剂， 反应 28.17h， 生成 3-ethyl-9,10-dimethoxy-2-((1,2,3,4-tetrahydroisoquinolin-1-yl)methyl)-4,6,7,11b-tetrahydro-1H-pyrido[2,1-a]isoquinoline
  参考文献：
  名称：

  The synthesis and structure revision of NSC-134754

  摘要：

  已成功合成强效HIF途径抑制剂亚氨基嘌呤类似物NSC-134754，并已重新确定其结构。首次通过X射线晶体学确定了NSC-134754的立体化学，并证明只有一个立体异构体对HIF具有活性。

  DOI：

  10.1039/c3cc48189a

文献信息

• Methods for Sensitizing Cancer Cells to Inhibitors
  申请人：Sherman Michael

  公开号：US20090062222A1

  公开（公告）日：2009-03-05

  The present invention is based on the discovery that inactivation of the heat shock response in cancer cells significantly enhances their sensitivity to proteasome and Hsp90 inhibitors. The inventors have discovered novel compounds which exhibit low toxicity, inhibit the heat shock protein response and sensitize cancer cells to anti-cancer therapies. In general, the heat shock protein inhibitors of the present invention share a common structure, namely a 2H-benzo[a]quinolizine tricyclic ring. Also encompassed are methods for a high throughput screen to identify heat shock inhibitors that sensitize cancer cells to anti-cancer therapies.
• THERAPEUTICAL COMPOSITIONS FOR USE IN THE TREATMENT OF NON-MALIGNANT CONDITIONS ASSOCIATED WITH PHOSPHATIDYLINOSITOL-3-KINASE ACTIVATION: OVERGROWTH SPECTRUM, CUTANEOUS CAPILLARY MALFORMATIONS AND SEBORRHEIC KERATOSES
  申请人：UNIVERSITÉ DE BOURGOGNE

  公开号：US20210393570A1

  公开（公告）日：2021-12-23

  A method of treatment of PIK3CA Related Overgrowth Spectrum, cutaneous capillary malformations, and seborrheic kératoses by administration, to a patient in need, of a pharmaceutical composition including an inhibitor of heat-shock factor 1 (HSF1), wherein the inhibitor of heat-shock factor 1 is selected among one or more of Triptolide, Minnelide, Kribb11, Quercetin, QC-12, Quercetin derivatives, KNK437, Stresgenin B, Emunin, NZ28, Cantharidin, Rocaglamide A, Rohinitib, Rohinitib-Cantharidin hybrids ligands, Arctigenin, and pharmaceutically acceptable derivatives, salts and solvates thereof.